Wells Fargo & Company Candel Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 6,344 shares of CADL stock, worth $40,030. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,344
Previous 115
5416.52%
Holding current value
$40,030
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding CADL
# of Institutions
49Shares Held
5.97MCall Options Held
82.9KPut Options Held
56K-
Northpond Ventures, LLC1.94MShares$12.2 Million41.58% of portfolio
-
Black Rock Inc. New York, NY823KShares$5.19 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA819KShares$5.17 Million0.0% of portfolio
-
State Street Corp Boston, MA473KShares$2.98 Million0.0% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA406KShares$2.56 Million1.27% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $182M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...